Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.84 USD
0.00 (0.42%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.84 0.00 (0.35%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 181 - 200 ( 325 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results from IVPRP Approach in Hurler and Hunter Syndrome Models Suggest Potential Breakthrough To Us; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
March and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY:15 Update; Gene Editing Programs Begin Clinical Testing in 2016; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Data Support Ongoing and Planned Gene Editing Studies in Hematopoietic Stem Cells; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results at ASH Bolster Sangamo''s ZFN Platform; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sangamo Is Cleared to Initiate In-Vivo Human Testing of its ZFN Based Protein Replacement Platform for Hemophilia B; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials: Cash Balance Supports Multiple Ongoing Programs; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Week Ahead in Life Sciences - Upcoming Events for the Week of September 14th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 14thThis report contains brief updates on the following: BIOD, CDTX, SGMO, EPZM, LXRX, NVAX, RPTP. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sangamo Regains Rights to Hemophilia Program; Still on Track to Submit IND for Hemophilia B Before Year End;Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L